Anshel Bright Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
grad_student
Research Areas
Biography and Research Information
OverviewAI-generated summary
Anshel Bright's research focuses on the evaluation of drug formulations and their effects in vivo. Their work has investigated nanocrystal-formulated Zileuton, a poorly soluble drug, examining its risk assessment and the mucosal immune profile following oral administration in Sprague Dawley rats. This research specifically looked at the association between the drug formulation and cytokine expression in the intestinal mucosa. Bright's publications include "Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats" (2023) and "P22-20 Risk assessment of Nanocrystal Formulated Zileuton (a poorly soluble BCS-II oral drug) using In Vivo Model" (2022). Bright has collaborated with researchers Sangeeta Khare, K.J. Harris, and Kuppan Gokulan, all from the National Center for Toxicological Research.
Metrics
- h-index: 1
- Publications: 2
- Citations: 5
Selected Publications
-
Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats (2023)
Collaboration Network
Top Collaborators
- Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats
- P22-20 Risk assessment of Nanocrystal Formulated Zileuton (a poorly soluble BCS-II oral drug) using In Vivo Model
- Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats
- P22-20 Risk assessment of Nanocrystal Formulated Zileuton (a poorly soluble BCS-II oral drug) using In Vivo Model
- P22-20 Risk assessment of Nanocrystal Formulated Zileuton (a poorly soluble BCS-II oral drug) using In Vivo Model
- P22-20 Risk assessment of Nanocrystal Formulated Zileuton (a poorly soluble BCS-II oral drug) using In Vivo Model
- P22-20 Risk assessment of Nanocrystal Formulated Zileuton (a poorly soluble BCS-II oral drug) using In Vivo Model
- Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats
- Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats
- Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats
Similar Researchers
Based on overlapping research topics